Bain Capital provided initial $300M funding to a firm alongside Bristol-Myers Squibb, which received Fast Track designation for SLE.

1 report, 1 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Bain Capital FDA

Keep exploring

Part of

Bristol-Myers Squibb and Bain Capital announced large deals regarding drug programs, including co-founding an acquired company, Aiolos Bio. All 1 developments

Within Tariffs benefit AI stocks, while Bristol-Myers Squibb and Bain Capital launch an immunology spinout.

The entities involved

Bain Capital
American alternative investment firm specialized in private equity, venture capital and credit products
- Ardian and Bain Capital discussed exit strategies within the private markets sector.Sun 04:06
- Bain Capital co-chairman and Eric Schmidt are reported to be backers of Solari Capital.Fri 11:57
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Jul 1bioxconomy.com